Annual Report: A Message From our Chief Scientific Officer
Veterans of clinical research know that we have entered a new era in which clinical trials are more targeted than ever to specific, biomarker-defined patient […]
Veterans of clinical research know that we have entered a new era in which clinical trials are more targeted than ever to specific, biomarker-defined patient […]
“Oncology is not for the faint of heart. It can be filled with a lot of joy, but there are really sad moments. You must […]
For the fourth consecutive year, Christopher A. Fausel, PharmD, challenged his friends, colleagues, and local businesses to support Hoosier Cancer Research Network through his participation […]
Hoosier Cancer Research Network will host meetings for Clinical Trial Working Groups during ASCO 2018. The following meetings will be at the Holiday Inn Chicago […]
Hoosier Cancer Research Network is moving to a new office location this spring, and our mailing address is changing. The following FAQ outlines how this […]
This month, Hoosier Cancer Research Network features our member institution Vanderbilt-Ingram Cancer Center (VICC) in Nashville, Tenn., and Nancy B. Davis, MD, associate professor of […]
As a member of the Hoosier Cancer Research Network, I am grateful to collaborate with outstanding investigators in the development of multi-center, investigator-initiated clinical trials. […]
During the 2023 ASCO Annual Meeting, Patrick J. Loehrer, MD, FACP, FASCO, received the ASCO Humanitarian Award in recognition of his work personifying ASCO’s mission […]
Hoosier Cancer Research Network (HCRN) announced today that Brian Stemme has been appointed Chief Executive Officer. Stemme, widely regarded as a champion of Indiana’s life […]
Hoosier Cancer Research Network (HCRN) is currently seeking a part-time communications intern. Students working toward a college degree in Marketing/Communications, Advertising, Public Relations or English […]
A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer Status: Closed to Accrual
NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene […]
Hoosier Cancer Research Network highlights Bently Doonan, MD, MS, oncologist and assistant professor in the division of hematology & oncology at the university of Florida […]
Hoosier Cancer Research Network (HCRN) will have an exhibitors booth at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Visit Booth #28115 to […]
Three Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials were highlighted during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago.
Researchers participating in HCRN GI14-198, recently reported findings in the European Journal of Cancer. The study was a phase II randomized, double-blind study of mFOLFIRINOX plus […]
Meet Hatim Sabaawy, MD, PhD Hatim Sabaawy, MD, PhD, of the University of Colorado Cancer Center is the Director of Personalized Medicine in the Division […]
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Status: Open to Accrual
Operations Associate Thao supports the operations team throughout the life of all HCRN trials, collaborating with each of the project managers to ensure seamless support […]
Operations Associate Amber supports the operations team throughout the life of all HCRN trials, collaborating with each of the project managers to ensure seamless support […]
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter